UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/09/20
UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 11/09/20
UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020Business Wire • 11/02/20
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial GrowthBusiness Wire • 09/09/20
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary IncontinenceBusiness Wire • 08/27/20
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 08/10/20
UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020Business Wire • 08/03/20
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/10/20
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/02/20
UroGen Pharma Ltd. (URGN) CEO Elizabeth Barrett on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/12/19
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/12/19